Study of MDX-1411 Given Every 14 Days With Pre-medications to Subjects With Clear Cell Kidney Cancer.

A Phase 1, Open-Label, Multicenter Dose-escalation, Multidose Study of MDX1411 Administered Every 14 Days in Subjects With Advanced or Recurrent Clear Cell Renal Cell Carcinoma

Status

Completed

Phases

Phase 1

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00656734

Acronym

MDX1411-01

Enrollment

Registered

2008-04-11

Start date

2008-04-30

Completion date

2010-06-30

Last updated

2013-05-14

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Kidney Cancer

Keywords

Medarex Inc.

Brief summary

To determine the highest and safest tolerated dose of MDX-1411 for the treatment of clear cell renal cell carcinoma (Kidney cancer).

Detailed description

Subjects will be assigned one dose upon enrollment and will continue with the same dose throughout the study. The maximum duration for the study is two and a half years for a total of 17 cycles.

Interventions

BIOLOGICALMDX 1411

MDX-1411 (fully human monoclonal antibody) administered as an i.v. infusion for up to 5 doses per cycle, with a maximum of 17 cycles total

Study design

Allocation

NON_RANDOMIZED

Intervention model

SINGLE_GROUP

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

* Histologically confirmed diagnosis of RCC with clear cell component * Measurable disease * Treated with up to 6 prior systemic therapies for advanced/recurrent disease or have become intolerant to a systemic therapy * Subjects with treated brain metastases must be without magnetic resonance imaging (MRI) evidence of progression for at least 8 weeks and off steroids for at least 4 weeks to be eligible * At least 28 days since the last chemotherapy * At least 28 days before the first dose of MDX 1411 since any major surgery * ECOG performance status 0-2 * No known positivity for human immunodeficiency virus (HIV), Hep B or C

Exclusion criteria

* Previous treatment with any other anti-CD70 antibody * Active infection requiring i.v systemic therapy within 28 days before first dose * Evidence of bleeding diathesis or coagulopathy * Active autoimmune disease requiring immunosuppressive therapy * Known current drug or alcohol abuse * Any underlying medical condition which will make the administration of MDX 1411 hazardous * Psychiatric illness or social situation that would preclude study compliance

Design outcomes

Primary

Measure	Time frame
Determine the safety profile of MDX 1411	duration of study
Determine the maximum tolerated dose of MDX 1411	duration of study

Secondary

Measure	Time frame
Determine the best overall response rate (BORR)	Day 38-42 of each cycle

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026